NTRB: Expanding Footprint And Boosting Patent Protection & Share Liquidity
By M. Marin
NTRB:NASDAQ
READ THE FULL NTRB RESEARCH REPORT
Expanding Footprint & IP Protection to Multiple Markets…
Nutriband Inc. (NTRB:NASDAQ) is an emerging a biopharma and medical device company that is developing a portfolio of transdermal pharmaceutical products. The company continues to move its product portfolio forward, expand its addressable market, gain traction, as illustrated by recent revenue growth, and boost the trading liquidity of its shares. The company’s initial focus is on solutions to help mitigate the abuse of opioids such as fentanyl and other addictive drugs. To expand its geographic footprint, Nutriband recently registered a new location in Ecuador, consistent with the goal to expand into the South American market.
NTRB's initial development focus is a Fentanyl transdermal patch that leverages its AVERSA™ technology. A recently signed feasibility agreement with Kindeva Drug Delivery (formerly 3M Drug Delivery Systems) is expected to accelerate AVERSA Fentanyl’s commercialization. Nutriband recently received a Notice of Allowance from the Canadian Intellectual Property Office for the AVERSA Abuse Deterrent Transdermal Technology Patent. The company already has patent protection in the U.S. and Mexico. Thus, with this Canadian patent, NTRB’s IP is protected across North America. Additionally, other patents have been granted in Europe, Japan, Korea, Russia and Australia. Patent protection in China is pending. Separately, NTRB has initiated the application process to dual list its shares on Upstream and Nasdaq to expand the pool of potential investors in and increase trading liquidity of NTRB shares.
The company believes its technology is consistent with – and could be additive to – government regulatory actions to address the opioid crisis. The U.S. DEA (U.S. Drug Enforcement Administration) is aggressively attempting to mitigate the sales and harmful impact of fentanyl and other abusive drugs. For instance, as part of what the agency calls “The One Pill Can Kill” initiative, with its law enforcement partners, DEA seized more than 10.2 million fentanyl pills and about 980 pounds of fentanyl powder from May 23, 2022, through Sept. 8, 2022. Moreover, the agency noted that fentanyl is sold in a variety of “bright colors, shapes, and sizes,” with rainbow fentanyl was first reported to the DEA in February 2022. Subsequently, the agency has seized rainbow fentanyl in 21 states.
The company's initial focus is on solutions to help mitigate the abuse of opioids such as fentanyl and other addictive drugs, including buprenorphine and methylphenidate. The need to address the opioid epidemic in the U.S. and globally creates opportunities for solutions such as those that Nutriband is developing. Transdermal drug delivery systems have gained traction in recent years, including the widespread use of nicotine and pain patches, partially due to their convenience and effectiveness. Transdermal drug delivery methods are less intrusive than many other delivery mechanisms and can be absorbed evenly through the skin into the blood system.
Nutriband's lead technology is an abuse deterrent fentanyl transdermal system, incorporating its abuse deterrent technology, AVERSA®. AVERSA is a patented technology and NTRB is optimistic about its prospects. The company's initial focus is on solutions to help mitigate the abuse of opioids such as fentanyl and other addictive drugs, including buprenorphine and methylphenidate. The need to address the opioid epidemic in the U.S. and globally creates opportunities for solutions such as those that Nutriband is developing.
To expand its geographic footprint and address the South American market, Nutriband recently registered a new company branch located in Ecuador, South America. The branch is consistent with the company’s goal to expand into the South American market. Nutriband intends to expand its product offering to the region through product registration and contract services.
… And Boosting Patent Protection…
Nutriband recently received a Notice of Allowance from the Canadian Intellectual Property Office for the AVERSA Abuse Deterrent Transdermal Technology Patent. The company already has patent protection in the U.S. and Mexico. With this Canadian patent, NTRB’s IP is protected across North America. Additionally, other patents have been granted in Europe, Japan, Korea, Russia and Australia. Patent protection in China is pending.
… And Boosting Share Trading Liquidity
NTRB has initiated the application process to dual list its shares on Upstream and Nasdaq to enable domestic and international investors using digital currency, and other payments, to invest in NTRB shares. This is consistent with the company’s goal to increase trading liquidity of NTRB shares. Separately, another step that is consistent with the goal to increase NTRB trading liquidity is that following the company’s recent authorization to recover 1.2 million shares, the shares were cancelled and NTRB’s board approved a subsequent 7:6 forward split of NTRB shares.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
